Teva Pharm Third-Quarter Profit Tops Estimates as Branded Drugs Gain

Reuters

Nov 05

JERUSALEM, Nov 5 (Reuters) - Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington's disease and schizophrenia.

Shares in the world's largest generic drugmaker were up 11.7% in premarket trading.

The company said it earned 78 cents per diluted share, excluding one-time items, in the July to September quarter, up from 69 cents a share a year earlier. Revenue was up 3% in dollar terms at $4.48 billion.

Analysts had forecast earnings of 67 cents per share ex-items for the Israel-based company on revenue of $4.34 billion, LSEG I/B/E/S data showed.

The group revised down its 2025 revenue estimate to $16.8-$17.0 billion from $16.8-$17.2 billion and updated its adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581722458"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581722458\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581722458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581722458","market":"us","top_or_hot":-1,"title":"Teva Pharm Third-Quarter Profit Tops Estimates as Branded Drugs Gain","media":"Reuters","content":"<html><head></head><body><p>JERUSALEM, Nov 5 (Reuters) - <a href=\"https://laohu8.com/S/TEVA\">Teva Pharmaceutical Industries</a> reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington&#39;s disease and schizophrenia.</p><p>Shares in the world&#39;s largest generic drugmaker were up 11.7% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/59036f5406f6476f9a3f78e83d7b5d08\" tg-width=\"538\" tg-height=\"164\"/></p><p>The company said it earned 78 cents per diluted share, excluding one-time items, in the July to September quarter, up from 69 cents a share a year earlier. Revenue was up 3% in dollar terms at $4.48 billion.</p><p>Analysts had forecast earnings of 67 cents per share ex-items for the Israel-based company on revenue of $4.34 billion, LSEG I/B/E/S data showed.</p><p>The group revised down its 2025 revenue estimate to $16.8-$17.0 billion from $16.8-$17.2 billion and updated its adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharm Third-Quarter Profit Tops Estimates as Branded Drugs Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharm Third-Quarter Profit Tops Estimates as Branded Drugs Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>JERUSALEM, Nov 5 (Reuters) - <a href=\"https://laohu8.com/S/TEVA\">Teva Pharmaceutical Industries</a> reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington&#39;s disease and schizophrenia.</p><p>Shares in the world&#39;s largest generic drugmaker were up 11.7% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/59036f5406f6476f9a3f78e83d7b5d08\" tg-width=\"538\" tg-height=\"164\"/></p><p>The company said it earned 78 cents per diluted share, excluding one-time items, in the July to September quarter, up from 69 cents a share a year earlier. Revenue was up 3% in dollar terms at $4.48 billion.</p><p>Analysts had forecast earnings of 67 cents per share ex-items for the Israel-based company on revenue of $4.34 billion, LSEG I/B/E/S data showed.</p><p>The group revised down its 2025 revenue estimate to $16.8-$17.0 billion from $16.8-$17.2 billion and updated its adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL8N3WH1N2:1","article_id":"2581722458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581722458","pubTimestamp":1762349132,"columns":[{"name":"Earnings Express","id":26,"label_key":"express"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"随着品牌药物的增长，梯瓦制药第三季度利润超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":2},"content_text":"JERUSALEM, Nov 5 (Reuters) - Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington's disease and schizophrenia.Shares in the world's largest generic drugmaker were up 11.7% in premarket trading.The company said it earned 78 cents per diluted share, excluding one-time items, in the July to September quarter, up from 69 cents a share a year earlier. Revenue was up 3% in dollar terms at $4.48 billion.Analysts had forecast earnings of 67 cents per share ex-items for the Israel-based company on revenue of $4.34 billion, LSEG I/B/E/S data showed.The group revised down its 2025 revenue estimate to $16.8-$17.0 billion from $16.8-$17.2 billion and updated its adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}